Accelerated vaccine process

Developers of these vaccines followed all steps the FDA normally requires for vaccine production. The only difference is that the COVID-19 vaccines were given priority review and moved to the front of the production line.



Typical process



Accelerated process



All the same steps were taken, but in a prioritized process with multiple trials running in parallel

- Research & development
- Phase 1 clinical trials
- Phase 2 clinical trials
- Phase 3 clinical trials
- Manufacturing
- Distribution

Accelerated process step-by-step

Manufacturing accelerated by:
Years of previous research on related viruses and faster ways to manufacture vaccines, and enormous funding and worldwide cooperation



Research & development accelerated by:
Vaccine candidate creation taking place right after viral genome sequence discovery and use of previously developed disease vaccine platforms

Clinical trials accelerated by:
Large scale trial of volunteers made for quicker analysis and, U.S. government funding for manufacturing

Distribution accelerated by:
Vaccine distribution planning before vaccine approval

Clinical trials

Both FDA-approved COVID-19 vaccines are 95% effective